telmisartan / Generic mfg. - LARVOL DELTA

First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study. (IASLC-WCLC 2022) - "These positive results support the combination of Atez+Bev as a potential treatment option for non-Sq NSCLC with TBM≥10. This is the first trial to evaluate the combination of Bev and TBM≥10mut/Mb excluding other alterations with very good results, even superior to other ICI+chemotherapy combinations."

Clinical • IO biomarker • Immune Modulation • Inflammation • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • MDM2 • ROS1 • STK11 • TMB

Telmisartan Repurposing Targets Novel Biomarkers for Precision Colorectal Cancer Therapy. (PubMed, Pharmaceutics) - "Based on in silico predicted deleterious mutations and subsequent molecular docking-based virtual screening, Telmisartan, Dutasteride and Venetoclax were prioritized. Conclucions: Our findings conclude that Telmisartan is a promising candidate for drug repurposing for CRC treatment and capable of modulating selected novel biomarkers CLUH and SLC11A2. However, further multi-omics-based confirmatory studies and pre-clinical validation studies are needed in the future to confirm the long-term efficacy of this repositioning strategy."

Biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor • SLC11A2

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. (PubMed, JAMA Oncol) - P2 | "This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) included treatment-naive patients aged 18 years or older with confirmed stage IIIB-IV nonsquamous NSCLC with TMB of 10 or more mutations/megabase and no EGFR, ALK, STK11, MDM2, or ROS1 alterations. These findings suggest that atezolizumab with bevacizumab is a potential treatment for high-TMB nonsquamous NSCLC. ClinicalTrials.gov Identifier: NCT03836066."

IO biomarker • Journal • Cardiovascular • Dermatology • Fatigue • Hypertension • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pruritus • Renal Disease • Solid Tumor • ALK • EGFR • ROS1 • STK11 • TMB

Bioengineered Amphiphilic Chitosan Nanocarriers for Improved Oral Absorption of Poorly Soluble Antihypertensive Agents. (PubMed, Recent Adv Drug Deliv Formul) - "For BCS Class II and IV medications like telmisartan, amlodipine, nifedipine, and carvedilol, these restrictions are especially important and call for creative delivery methods. This review carefully scrutinizes the chemistry and self-assembly processes, formulation strategies, pharmacokinetic advantages, safety-related issues, and potential uses of amphiphilic chitosan-based nanocarriers. All things considered, these technologies represent an interesting emerging delivery approach that may improve the oral bioavailability and therapeutic efficacy of poorly soluble antihypertensive drugs."

Journal • Cardiovascular • Hypertension

Polypharmacy and skin cancer: a new vision for skin cancer pathogenesis - photocarcinogenicity-mediated due to nitrosamine formation during telmisartan/tamsulosin intake (EADV 2026) - No abstract available

Genetic Disorders • Oncology • Skin Cancer

Efficacy of Terminalia arjuna in essential hypertension: A randomized controlled study. (PubMed, Explore (NY)) - "The results provide evidence that the test drug is beneficial in primary hypertension. The test drug reduced systolic and diastolic blood pressure significantly more than the placebo."

Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Hypertension

A Single-Center Clinical Trial of Telmisartan for the Treatment of Persistent Retinal Pigment Epithelium Detachment (ChiCTR) - P4 | N=30 | Not yet recruiting | Sponsor: Zhongshan Ophthalmic Center,Sun Yat-sen University; Zhongshan Ophthalmic Center,Sun Yat-sen University

New P4 trial

Ligustrazine with telmisartan mitigates the progression of diabetic cardiomyopathy by reducing ER stress, apoptosis, and myocardial fibrosis. (PubMed, Mol Cell Biochem) - "A combination of LIG40 and TEL5 provided greater cardiac protection, with a significant improvement in cardiac electrical rhythm and hemodynamics, accompanied by a marked reduction in UPRER, myocardial apoptosis, and fibrosis, indicating the efficacy of the combination therapy. Combining LIG, a phytopharmaceutical, with TEL offers greater efficacy in DCM, provides a novel therapeutic strategy, and is compelling and holds value in treating DCM."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Fibrosis • Immunology • Metabolic Disorders

Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus. (PubMed, J Hum Hypertens) - "Secondary analyses were also not significantly different. Overall, this study did not detect sufficient evidence that telmisartan reduces NODM risk compared with losartan, valsartan, or candesartan."

Journal • Diabetes • Metabolic Disorders • PPARG

CONTROL-IHD Study: 24-h BP Control with Metoprolol-Telmisartan FDC in Hypertension and Stable Ischemic Disease. (PubMed, Adv Ther) - "Metosartan® demonstrated effective and sustained 24-h BP reduction and good tolerability in Indian patients with hypertension and stable IHD. The reductions observed during the early post-application and late dosing-interval periods suggest sustained BP lowering over 24 h."

Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertension

Efficacy and Safety of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=170 | Terminated | Sponsor: HB BioTech, LLC | Trial completion date: Feb 2027 ➔ Sep 2026 | Suspended ➔ Terminated | Trial primary completion date: Jan 2027 ➔ Sep 2026; Decision to terminate study due to a lack of efficacy in this study population. There were no safety concerns identified that contributed to this decision.

Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Mood Disorders • Psychiatry

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Headache) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Neurology) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • Review • CNS Disorders • Migraine • Pain

Effect of amlodipine and telmisartan on bone metabolism markers in newly diagnosed hypertensive patients. (PubMed, Bioinformation) - "Telmisartan significantly reduced PTH and IL-6 levels while enhancing BS-ALP and transiently increasing osteocalcin, whereas Amlodipine demonstrated only a temporary rise in BS-ALP. Thus, data shows the telmisartan may provide additional benefits on bone remodeling and skeletal health in hypertensive patients at risk of fragility."

Journal • Cardiovascular • Hypertension • IL6

Real-World Effectiveness of Azelnidipine/Telmisartan Fixed-Dose Combination as Initial Therapy in Newly Diagnosed Hypertension: Data from ACT-HTN Study (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiovascular • Hypertension

Telmisartan-based monotherapy and combination regimens for blood pressure control in adults with hypertension: a systematic review, meta-analysis, and GRADE assessment. (PubMed, BMC Cardiovasc Disord) - "Telmisartan-based regimens, particularly fixed-dose and multidrug combinations, effectively reduce office and ambulatory blood pressure and improve blood pressure response, with broadly comparable short-term safety and less edema. These effect sizes are comparator-dependent, and certainty of evidence for absolute blood pressure control achievement and for major adverse events is very low; heterogeneity, limited long-term data, and a predominance of Asian-population trials warrant cautious interpretation pending larger, higher-quality, and more geographically diverse confirmatory studies."

Clinical • Journal • Monotherapy • Retrospective data • Review • Cardiovascular • Hypertension • Pain

Apical Hypertrophic Cardiomyopathy Mimicking Wellens Syndrome: A Diagnostic Challenge in a Patient Presenting With Recurrent Angina. (PubMed, Cureus) - "Treatment with bisoprolol, telmisartan, and atorvastatin resulted in complete symptom resolution, and the patient remained asymptomatic during follow-up. This case highlights the importance of considering ApHCM in the differential diagnosis of patients presenting with giant T-wave inversion and suspected acute coronary syndrome, as recognition of its characteristic electrocardiographic and echocardiographic features can facilitate an accurate diagnosis and help avoid misinterpreting Wellens-like electrocardiographic patterns as true Wellens syndrome."

Journal • Acute Coronary Syndrome • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Diabetes • Hypertension • Hypertrophic Cardiomyopathy • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus

Progress in Synthesis and Pharmacology of Telmisartan. (PubMed, Chem Biodivers) - "This review also discusses its two mechanisms of action: the Renin-Angiotensin-Aldosterone System (RAAS) inhibitor and partial agonist activity at the Peroxisome Proliferator-activated receptor gamma (PPARγ) receptor. Effective repurposing of this drug for various diseases like chronic kidney illness, diabetes, fatty liver, and Alzheimer's has also been discussed."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Diabetes • Hypertension • Metabolic Disorders • Nephrology • PPARG

Pharmaceutical pollution in a wastewater-impacted coastal ecosystem. (PubMed, Environ Pollut) - "Out of 95 target analytes, 15 were detected, with the most frequent detections being telmisartan (83%), flecainide (52%), memantine (37%), caffeine (28%) and tramadol (23%). Follow-up sampling revealed higher pharmaceutical concentrations in sea foam relative to seawater, suggesting enrichment within the air-water interface and potential transport to terrestrial environments via coastal aerosols. Overall, our findings demonstrate the role of wastewater in pharmaceutical pollution, with plants and algae emerging as potential bioindicators."

Journal

Effects of a novel low-dose triple combination on blood pressure variability: results from the TRIDENT trial (ESC 2026) - "Participants were randomised to a triple single-pill combination of telmisartan 20 mg, amlodipine 2.5 mg and indapamide 1.25 mg or matching placebo, in addition to usual care, with a mean follow-up of 3 years. Similar reductions were observed for diastolic BPV across SD (−0.84 mmHg; 95% CI −1.24 to −0.43; p<0.001), CV (−0.47%; 95% CI −0.92 to −0.02; p=0.039) and ARV (−0.84 mmHg; 95% CI −1.39 to −0.30; p=0.003), with no difference in VIM (−0.07; 95% CI −0.44 to 0.30; p=0.70).CONCLUSIONSIn patients with prior intracerebral haemorrhage receiving usual care, a low-dose triple single-pill combination reduced SD, CV and ARV of systolic and diastolic BP variability compared with placebo, but not VIM. As VIM adjusts for mean BP, the lack of a significant difference in VIM indicates that reductions in SD, CV and ARV were predominantly attributable to mean BP lowering."

Cardiovascular

Effects of a novel low-dose triple combination antihypertensive pill on blood pressure, according to background blood pressure medications: results from the TRIDENT trial (ESC 2026) - "On behalf: TRIDENT Investigators BACKGROUNDThere is increasing interest in the potential for low-dose combination antihypertensives to improve blood pressure (BP) control, but limited evidence exists of their long-term effects or efficacy when added to other regimens.METHODSIn TRIDENT, a multinational, double-blind, randomized, placebo-controlled trial of patients with prior intracerebral haemorrhage and a systolic BP 130-160mmHg who successfully completed a 2-week, single-blind, active run-in phase, eligible patients were randomized to a triple-pill containing telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg or matching placebo, on top of usual care...When analyses were restricted to those whose background BP regimen comprised one or more medications in the same class as the intervention (ARB, calcium channel blocker, diuretic; n=994), BP differences vs placebo were 16/8, 15/8 and 12/5 mmHg according to whether participants received 1, 2 or 3 background BP..."

Cardiovascular • Hypertension

Risk of incident gout and major adverse cardiovascular events according to angiotensin receptor blocker type in amlodipine-based combination therapy: a nationwide cohort study (ESC 2026) - "Among ARBs, losartan uniquely inhibits the urate transporter URAT1 in the proximal tubule, exerting a uricosuric effect, whereas valsartan, telmisartan, and olmesartan lack this property. In amlodipine-based first-line combination therapy, losartan was the only ARB associated with a reduced risk of new-onset gout, consistent with its uricosuric effect. All ARBs provided comparable MACE reduction. Losartan-based combination may offer additional benefit in mitigating gout risk among hypertensive patients."

Adverse events • Combination therapy • Cardiovascular • Hypertension • Myocardial Infarction

Olmesartan-Associated Sprue-Like Enteropathy With Concurrent Intestinal Methanogen Overgrowth and Secondary Disaccharidase Deficiencies: Delayed Diagnosis With Histologic and Enzymatic Recovery After Drug Discontinuation (ACG 2026) - "Olmesartan was switched to telmisartan, and IMO treated with neomycin 500 mg twice daily and rifaximin 550 mg three times daily for 14 days. Mayo Clin Proc. 2012;87:732-738."

Anorexia • Cardiovascular • Celiac Disease • Gastrointestinal Disorder • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammation

Frequency and Profiles of Drug Combinations Constituting the Triple Whammy in Japan: An Analysis of a Patient Estimation Database. (PubMed, Pharmacy (Basel)) - "In the single-agent analysis, loxoprofen was the most commonly prescribed NSAID (66.3%), olmesartan (19.4%) and telmisartan (15.9%) were the predominant RAS inhibitors, and furosemide (19.6%) and spironolactone (16.0%) were the most frequently used diuretics...By contrast, sacubitril/valsartan was the most common RAS inhibitor when combined with diuretics, frequently utilized for heart failure management...Heart failure patients prescribed these two causative drugs are highly vulnerable to "triple whammy" prescriptions. Awareness of inadvertent NSAID additions is warranted to mitigate potential AKI risks."

Journal • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

DDI: A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Huons Co., Ltd.

New P1 trial